Clinical trials: Ovary Disease
Infertility, Female, Polycystic Ovary Syndrome
IVM Versus IVF: Differences in Patients' Emotional Adjustment and Quality of Life
Patients who undergo in vitro fertilization with or without intracytoplasmic sperm injection (IVF / ICSI) often experience an impact on their quality of life and emotional maladjustment to treatment and outcome.
- Conditions
- Infertility, Female, Polycystic Ovary Syndrome, Psychological Stress, Quality of Life
- Trial name
- EMAQOLIVMIVF (NCT03066349)
- Testing
- Questionnaires
- Where
- Belgium
- Volunteers
- 149 people
- Sponsor
- Universitair Ziekenhuis Brussel
Ovarian Cancer, Ovarian Neoplasm
Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival
MIRRORS "Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery \& Survival" is a new United Kingdom based prospective feasibility study the purpose of which is to establish the feasibility of…
- Conditions
- Ovarian Cancer, Ovarian Neoplasm, Ovarian Neoplasm Epithelial, Fallopian Tube Cancer
- Trial name
- MIRRORS (NCT04402333)
- Testing
- Robotic Interval Debulking Surgery
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Ovarian Cancer
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
This study is an interventional, single-arm, open-label clinical trial. To evaluate the safety and efficacy of Fluzoparib as neoadjuvant therapy in patients with FIGO stage III and IV , BRCA mutations or HRD positive epithelial…
- Trial name
- NCT06541314
- Testing
- Fluzoparib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qilu Hospital of Shandong University
Ovarian Cancer, Fallopian Tube Cancer
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
Immunotherapy is a novel way to treat cancer and does so by targeting the immune system to destroy tumor cells. Many different therapeutic vaccines have been evaluated in phase 1, 2, and even phase 3 trials.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01416038
- Testing
- DPX-Survivac, low dose cyclophosphamide (oral)
- Where
- 7 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Ovarian Cancer With Peritoneal Carcinosis
Interest of the Manual Exploration as a Supplement to the Coelioscopy in the Evaluation of the Resectability of Peritoneal Carcinosis
This is a Multicenter prospective diagnostic study.
- Trial name
- CARPEMAN (NCT02493972)
- Testing
- GelPort, laparotomy
- Where
- 5 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Francois Baclesse
Polycystic Ovary Syndrome
Berberine Phytosome for Signs and Symptoms of Polycystic Ovary Syndrome (PCOS)
This multicenter, randomized, controlled clinical trial aims to evaluate the effectiveness of berberine phytosome supplementation in improving signs and symptoms associated with polycystic ovary syndrome (PCOS).
- Trial name
- NCT07465575
- Testing
- Berberine Phytosome (Sophy®), Lifestyle Advice
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT06469281
- Testing
- 27T51, Cemiplimab, Bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Advanced Solid Tumours, Breast Cancer
A Study of IMP4297 in Patients With Advanced Solid Tumors
This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered orally once every day to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be…
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03508011
- Testing
- IMP4297
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- Impact Therapeutics, Inc.
Ovarian Cancer
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer
The primary objective of this randomized phase II trial is to compare progression-free survival (PFS) in patients randomized to NGR-hTNF plus an anthracycline versus patients randomized to an anthracycline alone
- Trial name
- NGR018 (NCT01358071)
- Testing
- NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin
- Where
- 8 sites in Italy, United Kingdom
- Volunteers
- 119 people
- Sponsor
- AGC Biologics S.p.A.
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Fallopian Tube Cancer, Ovarian Cancer
Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: It is not yet known if treatment for recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer is more effective if it is begun when blood levels of CA 125 become elevated rather than waiting for other…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00002895
- Testing
- chemotherapy
- Where
- 21 sites in Austria, Belgium and 8 more
- Volunteers
- 1,400 people
- Sponsor
- Medical Research Council
Polycystic Ovary Syndrome
Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116
This study will be conducted in a single center, double-blind with 6 dose escalation groups to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of BAY1161116.
- Trial name
- NCT03119077
- Testing
- BAY1161116, Itraconazole
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Bladder Cancer, Breast Cancer
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in cancer survivors.
- Conditions
- Bladder Cancer, Breast Cancer, Colon Cancer, Endometrial Cancer
- Trial name
- TTBF (NCT05056077)
- Testing
- Counseling, Educational Intervention, Health Education
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- University of California, San Francisco
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Lung Cancer
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
RATIONALE: Vaccines made from the HER2/neu antigen may make the body build an immune response and kill tumor cells. Colony-stimulating factors such as GM-CSF increase the number of immune cells found in bone marrow or peripheral…
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00003002
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Female Infertility, Polycystic Ovary Syndrome
Evaluation of Clinical Outcomes and Costs of a Lifestyle Intervention in Obese Infertile Women
BACKGROUND: Obesity increases the risk of polycystic ovary syndrome (PCOS), characterized by anovulatory cycles, but it is also associated with reduced fertility even in ovulatory women.
- Conditions
- Female Infertility, Polycystic Ovary Syndrome, Obesity
- Trial name
- OF (NCT01483612)
- Testing
- Interdisciplinary lifestyle intervention
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- Université de Sherbrooke
Advanced Malignant Neoplasm, Breast Cancer
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases.
- Conditions
- Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
- Trial name
- NCT04503265
- Testing
- AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II
- Where
- 4 sites in United States
- Volunteers
- 122 people
- Sponsor
- AtlasMedx, Incorporated
Fallopian Tube Cancer, Ovarian Cancer
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer
- Trial name
- nCYT (NCT03593681)
- Testing
- Hysteroscopic cell sampling of the fallopian tube
- Where
- 10 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.